Top

Published in:

01-07-2009 | Short Communication

A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype

Authors: C. Pirkevi, S. Lesage, C. Condroyer, H. Tomiyama, N. Hattori, S. Ertan, A. Brice, A. N. Başak

Published in: Neurogenetics | Issue 3/2009

Abstract

The leucine-rich repeat kinase 2 (LRRK2) G2019S mutation is recognized as the most common cause of familial autosomal dominant and also sporadic forms of Parkinson disease (PD). A common founder has been described for most Europeans and all North Africans and Jews; besides, two distinct G2019S LRRK2 haplotypes were found in a small proportion of European families and in Japanese PD patients. This study revealed a Turkish patient heterozygous for the G2019S mutation sharing the Japanese haplotype. To the best of our knowledge, it is the first time that the G2019S-associated Japanese haplotype has been reported in a different population.

Available only for authorised users

Healy DG, Falchi M, O’Sullivan S et al (2008) Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol 7:583–590PubMedCrossRef

Hulihan MM, Ishihara-Paul L, Kachergus J et al (2008) LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. Lancet Neurol 7:591–594PubMedCrossRef

Zabetian CP, Hutter CM, Yearout D et al (2006) LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 79:752–758PubMedCrossRef

Kachergus J, Mata IF, Hulihan M et al (2005) Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 76(4):672–680PubMedCrossRef

Lesage S, Dürr A, Tazir M et al (2006) LRRK2 G2019S as a cause of Parkinson’s disease in North African Arabs. N Engl J Med 354(4):422–423PubMedCrossRef

Zabetian CP, Morino H, Ujike H et al (2006) Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease. Neurology 67:697–699PubMedCrossRef

Tomiyama H, Li Y, Funayama M et al (2006) Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson’s disease patients from 18 countries. Mov Dis 21(8):1102–1108CrossRef

Lesage S, Leutenegger AL, Ibanez P et al (2005) LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 77:330–332PubMedCrossRef

Title: A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype
Authors: C. Pirkevi
S. Lesage
C. Condroyer
H. Tomiyama
N. Hattori
S. Ertan
A. Brice
A. N. Başak
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Neurogenetics / Issue 3/2009
Print ISSN: 1364-6745
Electronic ISSN: 1364-6753
DOI: https://doi.org/10.1007/s10048-009-0173-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A LRRK2 G2019S mutation carrier from Turkey shares the Japanese haplotype

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Association between migraine and a functional polymorphism at the dopamine β-hydroxylase locus

Molecular analysis of NPC1 and NPC2 gene in 34 Niemann–Pick C Italian Patients: identification and structural modeling of novel mutations

The spectrum of somatic and germline NF1 mutations in NF1 patients with spinal neurofibromas

Novel mutations in the CDKL5 gene, predicted effects and associated phenotypes

Extended tracts of homozygosity identify novel candidate genes associated with late-onset Alzheimer’s disease

Interaction of the SPG21 protein ACP33/maspardin with the aldehyde dehydrogenase ALDH16A1